N-isoamyl-N-(6-hydroxynaphthalene-2-sulfonyl)-D-valine tert-butyl ester | 1330577-93-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: N-isoamyl-N-(6-hydroxynaphthalene-2-sulfonyl)-D-valine tert-butyl ester
• 英文别名: N-Isoamyl-N-(6-hydroxy naphthalene-2-sulfonyl)-D-valine tert-butyl ester；tert-butyl (2R)-2-[(6-hydroxynaphthalen-2-yl)sulfonyl-(3-methylbutyl)amino]-3-methylbutanoate
• CAS: 1330577-93-9
• 化学式: C₂₄H₃₅NO₅S
• 分子量: 449.612
• InChiKey: YWHZLHSHXHVUPE-JOCHJYFZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  31
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  92.3
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  N-isoamyl-N-(6-hydroxynaphthalene-2-sulfonyl)-D-valine tert-butyl ester 在 hexanes-ethyl acetate 作用下， 以 盐酸 、 乙酸乙酯 为溶剂， 反应 16.0h， 以to afford the title compound as a colorless oil (0.26 g, 90% yield)的产率得到N-isoamyl-N-(6-hydroxynaphthalene-2-sulfonyl)-D-valine
  参考文献：
  名称：

  Selective hydroxamic acid based MMP-12 and MMP-13 inhibitors

  摘要：

  本发明提供了一个式（I）的化合物：所述化合物是MMP-12和/或MMP-13的抑制剂，因此可用于治疗MMP-12和/或MMP-13活性异常引起的疾病或疾病。因此，式（I）的化合物可用于治疗由MMP-12和/或MMP-13介导的疾病或疾病。最后，本发明还提供了包括式（I）的化合物的药物组合物。

  公开号：

  US08841291B2
• 作为产物：
  描述：

  D-valine t-butyl ester 在 水 、 potassium carbonate 、 三乙胺 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 生成 N-isoamyl-N-(6-hydroxynaphthalene-2-sulfonyl)-D-valine tert-butyl ester
  参考文献：
  名称：

  Potent and selective 2-naphthylsulfonamide substituted hydroxamic acid inhibitors of matrix metalloproteinase-13

  摘要：

  The matrix metalloproteinase enzyme MMP-13 plays a key role in the degradation of type II collagen in cartilage and bone in osteoarthritis (OA). An effective MMP-13 inhibitor would provide a disease modifying therapy for the treatment of arthritis, although this goal still continues to elude the pharmaceutical industry due to issues with safety. Our efforts have resulted in the discovery of a series of hydroxamic acid inhibitors of MMP-13 that do not significantly inhibit MMP-2 (gelatinase-1). MMP-2 has been implicated in the musculoskeletal side effects resulting from pan-MMP inhibition due to findings from spontaneously occurring human MMP-2 deletions. Analysis of the SAR of hundreds of previously prepared hydroxamate based MMP inhibitors lead us to 2-naphthylsulfonamide substituted hydroxamates which exhibited modest selectivity for MMP-13 versus MMP-2. This Letter describes the lead optimization of 1 and identification of inhibitors exhibiting >100-fold selectivity for MMP-13 over MMP-2 (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.08.087

文献信息

• [EN] SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS<br/>[FR] INHIBITEURS SÉLECTIFS DE MMP-12 ET MMP-13 À BASE D'ACIDE HYDROXAMIQUE
  申请人：NOVARTIS AG

  公开号：WO2010007027A1

  公开（公告）日：2010-01-21

  The present invention provides a compound of formula (I) said compound is inhibitor of MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-12 and/or MMP- 13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-12 and/or MMP-13. Finally, the present invention also provides pharmaceutical composition that include the compound of formula (I).

  本发明提供了一种具有化学式(I)的化合物，该化合物是MMP-12和/或MMP-13的抑制剂，因此可用于治疗由MMP-12和/或MMP-13异常活性特征的疾病或疾病。因此，化合物的化学式(I)可用于治疗由MMP-12和/或MMP-13介导的疾病或疾病。最后，本发明还提供了包括化学式(I)的化合物的药物组合物。
• SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS
  申请人：McQuire Leslie Wighton

  公开号：US20110112076A1

  公开（公告）日：2011-05-12

  The present invention provides a compound of formula (I) said compound is inhibitor of MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-12 and/or MMP-13. Finally, the present invention also provides pharmaceutical composition that include the compound of formula (I).

  本发明提供了一种式子为(I)的化合物，该化合物是MMP-12和/或MMP-13的抑制剂，因此可用于治疗MMP-12和/或MMP-13活性异常引起的疾病或疾病。因此，式(I)的化合物可用于治疗由MMP-12和/或MMP-13介导的疾病或疾病。最后，本发明还提供了包括式(I)的化合物的药物组合物。
• Selective hydroxamic acid based MMP-12 and MMP-13 inhibitors
  申请人：McQuire Leslie Wighton

  公开号：US08841291B2

  公开（公告）日：2014-09-23

  The present invention provides a compound of formula (I): said compound is inhibitor of MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-12 and/or MMP-13. Finally, the present invention also provides pharmaceutical composition that include the compound of formula (I).

  本发明提供了一个式（I）的化合物：所述化合物是MMP-12和/或MMP-13的抑制剂，因此可用于治疗MMP-12和/或MMP-13活性异常引起的疾病或疾病。因此，式（I）的化合物可用于治疗由MMP-12和/或MMP-13介导的疾病或疾病。最后，本发明还提供了包括式（I）的化合物的药物组合物。
• US8841291B2
  申请人：——

  公开号：US8841291B2

  公开（公告）日：2014-09-23
• Potent and selective 2-naphthylsulfonamide substituted hydroxamic acid inhibitors of matrix metalloproteinase-13
  作者：Ruben A. Tommasi、Sven Weiler、Leslie W. McQuire、Olivier Rogel、Mark Chambers、Kirk Clark、John Doughty、James Fang、Vishwas Ganu、Jonathan Grob、Ronald Goldberg、Robert Goldstein、Stacey LaVoie、Raviraj Kulathila、William Macchia、Richard Melton、Clayton Springer、Marc Walker、Jing Zhang、Lijuan Zhu、Michael Shultz

  DOI：10.1016/j.bmcl.2011.08.087

  日期：2011.11

  The matrix metalloproteinase enzyme MMP-13 plays a key role in the degradation of type II collagen in cartilage and bone in osteoarthritis (OA). An effective MMP-13 inhibitor would provide a disease modifying therapy for the treatment of arthritis, although this goal still continues to elude the pharmaceutical industry due to issues with safety. Our efforts have resulted in the discovery of a series of hydroxamic acid inhibitors of MMP-13 that do not significantly inhibit MMP-2 (gelatinase-1). MMP-2 has been implicated in the musculoskeletal side effects resulting from pan-MMP inhibition due to findings from spontaneously occurring human MMP-2 deletions. Analysis of the SAR of hundreds of previously prepared hydroxamate based MMP inhibitors lead us to 2-naphthylsulfonamide substituted hydroxamates which exhibited modest selectivity for MMP-13 versus MMP-2. This Letter describes the lead optimization of 1 and identification of inhibitors exhibiting >100-fold selectivity for MMP-13 over MMP-2 (C) 2011 Elsevier Ltd. All rights reserved.